Steven M Larson - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Steven M Larson

Showing results (221-230 of 300) with videos related to

Pageof 30

Sort By:

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 10, 2004

The CT motion quantitation of lung lesions and its impact on PET-measured SUVsYusuf E Erdi, Sadek A Nehmeh, Tinsu Pan, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2007

Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8Kim Kramer, John L Humm, Mark M Souweidane, et al.

Clinical Positron Imaging : Official Journal of the Institute for Clinical P.E.T|October 1, 2003

Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion GlycolysisSteven M. Larson, Yusuf Erdi, Timothy Akhurst, et al.

Theranostics|June 16, 2025

GPA33-pretargeted radioimmunotherapy with mono- and bivalent DOTA-based Lu-177-labeled radiohaptens in a mouse orthotopic liver xenograft model of metastatic human colorectal cancerAlexandre B Le Roux, Edward K Fung, Sang Gyu Lee, et al.

EJNMMI Research|January 24, 2016

Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modelingEdward K Fung, Sarah M Cheal, Shoaib B Fareedy, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2018

Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast CancerDaniel L J Thorek, Anson T Ku, Nicholas Mitsiades, et al.

Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 4, 2024

Patient metabolic profile defined by liver and muscle 18F-FDG PET avidity is independently associated with overall survival in gastric cancerGerardo A Vitiello, Vetri Sudar Jayaprakasam, Laura H Tang, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancerDana E Rathkopf, Michael J Morris, Josef J Fox, et al.

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 14, 2025

PET-CT-based host metabolic (PETMet) features are associated with pathologic response in gastroesophageal adenocarcinomaCharlie White, Vetri Sudar Jayaprakasam, Megan Tenet, et al.

Prostate Cancer and Prostatic Diseases|November 11, 2018

Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancerAmy J Weisman, Stephanie A Harmon, Timothy G Perk, et al.

Pageof 30

Search research articles

Showing results (221-230 of 300) with videos related to

Sort By:

Pageof 30

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 10, 2004

The CT motion quantitation of lung lesions and its impact on PET-measured SUVsYusuf E Erdi, Sadek A Nehmeh, Tinsu Pan, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2007

Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8Kim Kramer, John L Humm, Mark M Souweidane, et al.

Clinical Positron Imaging : Official Journal of the Institute for Clinical P.E.T|October 1, 2003

Theranostics|June 16, 2025

EJNMMI Research|January 24, 2016

Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modelingEdward K Fung, Sarah M Cheal, Shoaib B Fareedy, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2018

Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast CancerDaniel L J Thorek, Anson T Ku, Nicholas Mitsiades, et al.

Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 4, 2024

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancerDana E Rathkopf, Michael J Morris, Josef J Fox, et al.

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 14, 2025

PET-CT-based host metabolic (PETMet) features are associated with pathologic response in gastroesophageal adenocarcinomaCharlie White, Vetri Sudar Jayaprakasam, Megan Tenet, et al.

Prostate Cancer and Prostatic Diseases|November 11, 2018

Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancerAmy J Weisman, Stephanie A Harmon, Timothy G Perk, et al.

Pageof 30